Top Story

Statins reduced non-calcified coronary plaque in HIV patients

February 27, 2015

SEATTLE — Statin therapy may reduce the volume of non-calcified coronary plaque in patients with HIV and subclinical atherosclerosis, according to data presented here at CROI 2015.

“Numerous epidemiological studies have shown that coronary artery disease is a major cause of morbidity and mortality for patients living with HIV around the world today,” Janet Lo, MD, of the Massachusetts General Hospital and Harvard Medical School, said during an oral presentation. “Within the HIV population, statins have been demonstrated to improve lipids, endothelial function on markers of inflammation, and immune activation, as well as other effects. However, no studies have yet directly assessed the effects of statins on coronary plaque in HIV patients.”

Daniel Freitag, PhD In the Journals

Study Inflammation may be protective against long term CVD risk

February 27, 2015
Inflammation may have a protective effect on cardiovascular health, according to results of a large study by the Interleukin-1 Genetics consortium that examined the…
Marily Tavenner

CMS completes first week of ICD-10 end-to-end testing

February 26, 2015
The CMS concluded its first successful end-to-end testing week of the new ICD-10 coding, the agency announced in a blog post. “Testing allows us to identify areas…
In the Journals

CVD risk assessment priority for adults with diabetes, metabolic syndrome

February 26, 2015
Approximately one-quarter of adults with type 2 diabetes and metabolic syndrome face a cardiovascular disease risk of at least 20%, according to research published in…
FDA NewsDrug Pipeline

FDA grants orphan drug status to Factor Xa inhibitor antidote

February 26, 2015
The FDA has granted orphan drug designation to andexanet alfa for the treatment of patients with serious, uncontrolled bleeding events or who require emergency surgery…
More News Headlines »
Obesity Consults: Volume 2, Number 2 Obesity Forum 2014 Highlights

Obesity Consults: Volume 2, Number 2
Obesity Forum 2014 Highlights

This activity is supported by educational grants from Takeda Pharmaceuticals International, Inc., US Region and Orexigen Therapeutics, Inc; Eisai, Inc.; Novo Nordisk; Vivus, Inc.

Management of obesity is complex, factoring in psychological, environmental, and physiologic causes. Treatment options…
More »
Meeting News Coverage Video
Healio ISC2015 Goldstein1 th

VIDEO: New data support endovascular stroke therapy

February 20, 2015
NASHVILLE, Tenn. — In this video, Larry B. Goldstein, MD, FAAN, FANA, FAHA, professor of neurology and director…
More »
Best of Lipid Forum III

Best of Lipid Forum III

This activity is supported by an educational grant from Amgen, Inc.

Appropriate therapies for various dyslipidemias remain a challenge for practitioners struggling to reduce residual risk…
More »